<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04925934</url>
  </required_header>
  <id_info>
    <org_study_id>VIB7734.P2.S1</org_study_id>
    <secondary_id>2020-005528-12</secondary_id>
    <nct_id>NCT04925934</nct_id>
  </id_info>
  <brief_title>A Phase 2 of VIB7734 for the Treatment of Moderate to Severely Active SLE</brief_title>
  <acronym>RECAST SLE</acronym>
  <official_title>A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viela Bio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Viela Bio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734&#xD;
      for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus in&#xD;
      approximately 195 participants. The study duration will be 48 weeks, with a safety follow-up&#xD;
      through week 56.There will be 3 parallel arms - 2 active treatment and 1 placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 24, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo-controlled, parallel-arm study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants who achieve BICLA and OGC (oral glucocorticoid) reduction response at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Participants will have BICLA (BILAG 2004 Index-Based Combined Lupus Assessment) and oral glucocorticoid assessment at week 48.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with CLASI-A score ≥ 10 at Baseline (Day 1) who achieve ≥ 50% reduction from Baseline (Day 1) in CLASI-A score at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Cutaneous Lupus Erythematosus Disease Area and Severity Index will be measured at week 12. The scoring consists of 2 parts: inflammatory activity of the disease and damage done by the disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants achieving an SRI-4 response and an OGC dose ≤ 7.5 mg/day and ≤ Baseline (Day 1) dose of prednisone or equivalent at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>The SRI-4 (SLE Responder Index) is defined as meeting all criteria compared to baseline, (e.g. no worsening of symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants at OGC dose ≥ 10 mg prednisone or equivalent at Baseline (Day 1) who achieve an OCG of ≤ 7.5 mg/day prednisone or equivalent at Week 36 through Week 48</measure>
    <time_frame>Week 36 to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants achieving LLDAS (Lupus Low Disease Activity State) at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>LLDAS is a composite measure of SLE disease activity that measures 5 criteria: SLEDAI-2K ≤ 4, with no activity in major organ systems, no new lupus disease activity, PGA ≤ 1 (scale 0 to 3), current prednisone (or equivalent) dose ≤ 7.5 mg daily, tolerated maintenance doses of immunosuppressive drugs and approved biological agents.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants who experience AEs, SAEs, AESIs</measure>
    <time_frame>Baseline through Week 60</time_frame>
    <description>Safety evaluation will occur throughout the study.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">195</enrollment>
  <condition>Lupus Erythematosus, Systemic</condition>
  <arm_group>
    <arm_group_label>VIB7734 SC (dosing interval 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VIB7734 SC (dosing interval 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SC (dosing interval 3)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIB7734</intervention_name>
    <description>VIB7734</description>
    <arm_group_label>VIB7734 SC (dosing interval 1)</arm_group_label>
    <arm_group_label>VIB7734 SC (dosing interval 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo SC (dosing interval 3)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years to ≤ 70 years&#xD;
&#xD;
          -  Willing and able to understand and provide written informed consent.&#xD;
&#xD;
          -  Fulfill the 2019 European League Against Rheumatism/American College of Rheumatology&#xD;
             Classification Criteria for SLE&#xD;
&#xD;
          -  Disease duration of at least 6 months&#xD;
&#xD;
          -  Active SLE as indicated by presence of all the following:&#xD;
&#xD;
               1. SLEDAI-2K total score ≥ 6 at Screening, excluding fever, SLE headache, or organic&#xD;
                  brain syndrome.&#xD;
&#xD;
               2. SLEDAI-2K total score ≥ 4, excluding points attributable to any urine or&#xD;
                  laboratory results, immunologic measures, fever, SLE headache, or organic brain&#xD;
                  syndrome at Screening and Baseline (Day 1).&#xD;
&#xD;
               3. At least one of the following BILAG 2004 Index levels of disease at Screening:&#xD;
&#xD;
          -  BILAG A disease in ≥ 1 organ system&#xD;
&#xD;
          -  BILAG B disease in ≥ 2 organ systems d. PGA score ≥ 1 on a 0 to 3 visual analog scale&#xD;
             (VAS) at Screening&#xD;
&#xD;
        Have at least one of the following at Screening per central lab:&#xD;
&#xD;
          -  ANA ≥ 1:80&#xD;
&#xD;
          -  Anti-dsDNA antibodies elevated to above normal range as established by the central&#xD;
             laboratory (ie, positive results)&#xD;
&#xD;
          -  Anti-Smith antibodies elevated to above normal (ie, positive results)&#xD;
&#xD;
               1. Treatment with one or more disease-modifying anti-rheumatic drug (DMARD) or&#xD;
                  immunosuppressive medication: Any of the following medications each administered&#xD;
                  at conventional anti-rheumatic doses for treatment of SLE for at least 12 weeks&#xD;
                  before Screening (unless discontinued or dose adjusted for documented&#xD;
                  drug-related toxicity or size/weight), and at a stable dose (including route of&#xD;
                  administration) for a minimum of 8 weeks prior to Screening and maintained&#xD;
                  through Baseline (Day 1):&#xD;
&#xD;
               2. Treatment with OGC monotherapy (without the concomitant use of DMARDs or&#xD;
                  immunosuppressants):&#xD;
&#xD;
                    -  Average daily dose of PO prednisone ≥ 10 mg but ≤ 40 mg (or prednisone&#xD;
                       equivalent) for a minimum of 4 weeks prior to Screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any condition that, in the opinion of the Investigator, would interfere with the&#xD;
             evaluation of the IP or interpretation of participant safety or study results&#xD;
&#xD;
          -  History of allergy, hypersensitivity reaction, or anaphylaxis to any component of the&#xD;
             IP or a previous mAb or human Ig therapy&#xD;
&#xD;
          -  Active LN or active severe or unstable neuropsychiatric SLE&#xD;
&#xD;
          -  Current diagnosis of non-SLE vasculitis syndrome, mixed connective tissue disease, or&#xD;
             rheumatic (overlap) syndrome&#xD;
&#xD;
          -  Participation in another clinical study with an investigational drug within 4 weeks&#xD;
             before Day 1&#xD;
&#xD;
          -  Breastfeeding or pregnant women or women who intend to become pregnant anytime from&#xD;
             signing the ICF through 6 months after receiving the last dose of IP&#xD;
&#xD;
          -  Spontaneous or induced abortion, still or live birth, or pregnancy ≤ 4 weeks before&#xD;
             Screening&#xD;
&#xD;
          -  Known history of a primary immunodeficiency or an underlying condition such as known&#xD;
             human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Hepatitis B, Hepatitis C, active TB, any severe herpes infection, clinically active&#xD;
             infection, or opportunistic infection&#xD;
&#xD;
          -  History of clinically significant cardiac disease&#xD;
&#xD;
          -  History of cancer within the past 5 years, except:&#xD;
&#xD;
          -  In situ carcinoma of the cervix and Cutaneous basal cell&#xD;
&#xD;
          -  Receipt of a live-attenuated vaccine within 4 weeks before Day 1 Administration of&#xD;
             inactivated (killed) vaccines is acceptable&#xD;
&#xD;
          -  The use of immunosuppressants, biologics and DMARDS within the protocol defined&#xD;
             washout periods&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neema Dhungana</last_name>
    <role>Study Director</role>
    <affiliation>Horizon Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Horizon Therapeutics</last_name>
    <phone>1-866-479-6742</phone>
    <email>clinicaltrials@horizontherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Research of West Florida Inc - Clearwater</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765-2616</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maartje Brucculeri</last_name>
      <email>mbrucculeri@crwf.com</email>
    </contact>
    <investigator>
      <last_name>Robert Levin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida Inc - Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606-1246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Bryan</last_name>
      <email>cbryan@crwf.com</email>
    </contact>
    <investigator>
      <last_name>Edgard Janer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bluegrass Community Research Inc</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504-2931</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy Edwards</last_name>
      <email>bcr.net@att.net</email>
    </contact>
    <investigator>
      <last_name>Alexander Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DJL Clinical Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210-8509</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey Droppelman</last_name>
      <email>audrey.droppelman@djlresearch.com</email>
    </contact>
    <investigator>
      <last_name>Emily Box, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medication Management LLC</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408-7099</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Holley</last_name>
      <email>tiffany.holley@emailmm.com</email>
    </contact>
    <investigator>
      <last_name>Tauseef Syed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paramount Medical Research and Consulting LLC</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130-3483</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jackie Wittenmyer</last_name>
      <email>jwittenmyer5@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Isam Diab, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tekton Research Inc</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745-1485</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Yankyera</last_name>
      <email>RYankyera@tektonresearch.com</email>
    </contact>
    <investigator>
      <last_name>Paul Pickrell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Precision Comprehensive Clinical Research Solutions</name>
      <address>
        <city>Colleyville</city>
        <state>Texas</state>
        <zip>76034-5913</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shruti Parulekar</last_name>
      <email>shrutiparulekar@pccrsolutions.com</email>
    </contact>
    <investigator>
      <last_name>Dhiman Basu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spectrum Medical, Inc</name>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <zip>24541-1222</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tisha McMillon</last_name>
      <email>tisha.mcmillon@spectrummed.com</email>
    </contact>
    <investigator>
      <last_name>Sharukh Shroff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>June 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

